X‑Chem Announces Licensing of 50th Drug Discovery Program
WALTHAM, Mass. β July 26, 2018 β X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXTM) library drug discovery engine to the generation of novel small molecule therapeutics, today announced that it has licensed its 10th drug discovery program to date in 2018, bringing the total number of licensed programs to 50 since it launched its first target-based drug discovery partnership in 2012.
X‑Chem Enters Strategic Collaboration with Bristol-Myers Squibb
WALTHAM, Mass. β December 18, 2018 β X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXβ’) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb.
X‑Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca
WALTHAM, Mass. β January 17, 2018 β Small molecule discovery specialist X-Chem, Inc. today announced a significant expansion of their existing global drug discovery collaboration with the global biopharmaceutical company AstraZeneca.
X‑Chem and Vertex Expand Existing Partnership
WALTHAM, Mass. β January 4, 2019 β X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEXβ’) drug discovery engine to the generation of novel small molecule therapeutics, today announced the expansion of its collaboration with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).
Rumi Scientific Announces Partnership with X‑Chem for Development of Lead Candidate in Huntingtonβs Disease
NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) — Rumi Scientific (βRumiβ), a developer of therapies for rare and neurodegenerative diseases...
Maruho and X‑Chem Announce Drug Discovery Collaboration
WALTHAM, Mass. β September 4, 2019 - X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery partnership with Maruho Co., Ltd. (Maruho) to discover lead compounds for novel and challenging targets with applications for human diseases.
X‑Chem and Vertex Enter into Multi-Target Genetic Disease Collaboration
β Agreement will enable discovery of small-molecule leads against validated targets for severe, genetic diseasesβ X-Chem to receive upfront payment...